drugset / Trial / NCT02398513
Regorafenib Phase I Study in Mainland Chinese Patients
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to define the pharmacokinetic of Regorafenib administered orally as a single agent in Chinese patients with advance solid tumors. The second objective include the evaluation of safety, tolerability, and efficacy of Chinese patents treated with Regorafenib
Timeline
- Start
- 2015-04
- Primary completion
- 2015-11
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 160 mg | Oral |
Indications
No indication recorded.